Involvement of vanilloid receptor VR1 and prostanoids in the acid-induced writhing responses of mice.
We found that intraperitoneal injection of organic acids, such as propionic and lactic acid, are able to develop writhing responses in mice similarly as that of acetic acid. These acid-induced writhing reactions were significantly attenuated by capsazepine, a VR1 receptor-specific antagonist, but the phenylbenzoquinone-induced one was not, suggesting that the acids but not phenylbenzoquinone activate the VR1 receptor, which is involved in polymodal pain perception. Hoe 140, a bradykinin B2 receptor antagonist, also suppressed the acid-induced writhing response. Furthermore, these writhing responses were significantly suppressed after neonatal treatment with capsaicin, which treatment is known to destroy peripheral sensory afferent C-fibers. Capsazepine and Hoe 140 did not further attenuate the already reduced writhing responses of capsaicin-treated mice, suggesting that the acids stimulate the VR1 and the bradykinin B2 receptor in the pathway comprising sensory afferent C-fibers. On the other hand, indomethacin further significantly suppressed the writhing number of the capsaicin-treated animals, suggesting that the acid-induced pain perception requires prostanoid receptors not only in the pathway via capsaicin-sensitive C-fibers but also in other sensory pathways. These results provide the first evidence for the involvement of the vanilloid receptor in the acid-induced inflammatory pain perception via sensory C-fibers in addition to the known mediators bradykinin, neurokinins, and prostanoids.
Ikeda
Y
Y
Department of Pharmacology, School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan.
Ueno
A
A
Naraba
H
H
Oh-ishi
S
S
D019342:Acetic Acid / Q000494:pharmacology*; D000818:Animals; D000831:Animals, Newborn; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects*; D016227:Benzoquinones / Q000494:pharmacology; D001920:Bradykinin / Q000031:analogs & derivatives* / Q000494:pharmacology; D002211:Capsaicin / Q000031:analogs & derivatives* / Q000494:pharmacology; D004195:Disease Models, Animal; D005260:Female; D007213:Indomethacin / Q000494:pharmacology; D019344:Lactic Acid / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D010146:Pain / Q000139:chemically induced* / Q000378:metabolism* / Q000503:physiopathology; D010147:Pain Measurement; D011422:Propionates / Q000494:pharmacology*; D011453:Prostaglandins / Q000502:physiology; D011955:Receptors, Drug / Q000037:antagonists & inhibitors / Q000378:metabolism*; D011982:Receptors, Prostaglandin / Q000378:metabolism
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016227:Benzoquinones; D011422:Propionates; D011453:Prostaglandins; D011955:Receptors, Drug; D011982:Receptors, Prostaglandin; D019344:Lactic Acid; C029322:phenylbenzoquinone; C065679:icatibant; C029658:propionic acid; C071423:capsazepine; D019342:Acetic Acid; D002211:Capsaicin; D001920:Bradykinin; D007213:Indomethacin